Ono Pharmaceutical Co., Ltd.
Research Ono Pharmaceutical Co., Ltd. (4528.T) on Bullrun: market cap JPY 1.13T, P/E 14.9, dividend yield 3.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4528.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyJPY
- Market capJPY 1.13T
- P/E14.9
- Dividend yield3.2%
- Financial periodFY2026
- RevenueJPY 515.79B
- Revenue growth5.9%
- Net incomeJPY 69.77B
- Free cash flowJPY 83.55B
- Gross margin72.5%
Valuation Snapshot
latest market cap is JPY 1.13T; P/E is 14.9; dividend yield is 3.2%.
Peer valuation comparison
Latest P/E is 14.89x versus a Healthcare sector median of 21.69x (31.4% below).
Latest dividend yield is 3.22% versus a Healthcare sector median of 2.41% (33.6% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 515.79B | JPY 69.77B | JPY 83.55B | 72.5% | 148.41 | JPY 237.05B | JPY 120.94B | JPY 850.73B |
| FY2025 | JPY 486.87B | JPY 50.05B | JPY 74.47B | 69.6% | 106.41 | JPY 204.57B | JPY 146.68B | JPY 782.45B |
| FY2024 | JPY 502.67B | JPY 127.98B | JPY 89.83B | 74.7% | 266.57 | JPY 166.14B | JPY 8.86B | JPY 792.96B |
| FY2023 | JPY 447.19B | JPY 112.72B | JPY 145.11B | 75.4% | 230.79 | JPY 96.14B | JPY 9.17B | JPY 741.87B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 1.13T | 14.9 | 3.3% | 80 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 80 JPY, yield 3.2%.
| Year | Dividends/share |
|---|---|
| FY2026 | 80 JPY |
| FY2025 | 80 JPY |
| FY2024 | 80 JPY |
| FY2023 | 77 JPY |
About Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ono Pharmaceutical Co., Ltd.'s market cap?
Ono Pharmaceutical Co., Ltd.'s market capitalization is JPY 1.13T.
What is Ono Pharmaceutical Co., Ltd.'s P/E ratio?
Ono Pharmaceutical Co., Ltd.'s price-to-earnings (P/E) ratio is 14.9.
Does Ono Pharmaceutical Co., Ltd. pay a dividend?
Ono Pharmaceutical Co., Ltd. has a dividend yield of 3.2%.
What does Ono Pharmaceutical Co., Ltd. do?
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia.